Pay in 4 interest-free payments of $5.78 Learn more
Ships within 48 hours · Estimated delivery Oct 13 - Oct 18
Main GLP1 and Related Brands Leading GLP-1 medications in 2025 include semaglutide (marketed as Ozempic for diabetes and Wegovy for weight loss), liraglutide (Victoza for diabetes, Saxenda for weight loss), tirzepatide (Mounjaro for diabetes, Zepbound for weight loss), dulaglutide (Trulicity for diabetes) and oral semaglutide (Rybelsus)
These usually peak when a dose is increased and subside as the body adapts
People stop taking Rybelsus because the morning routine feels too demanding, quit injectables because weekly shots become burdensome, or stop Foundayo when nausea persists and no one helps adjust dosing or meal timing
Key gap: no human trial has been published, and no human pharmacokinetic study is widely available
So far, the trials seem to show: high reduction in weight, hovering around 28% for those on a 12-milligram dose self-reported improvements in cardiometabolic risk factors like high blood pressure, insulin, and fasting glucose promising results for type 2 diabetes and fatty liver disease a reduction in pain from knee osteoarthritis Retatrutide may be valuable for those who have had limited success with other weight loss drugs, have a higher BMI, or are at significant metabolic risk
Dosage Effect Dose-response findings belong to the specific clinical trial
US$ 20.32
US$ 28.93
US$ 29.06
US$ 22.53
US$ 20.87
US$ 28.60
